|
(ÁÖ)ÀÌÁö¼Ö·çÅØ |
GMPÀÎÁõ ÄÁ¼³ÅÏÆ® ¸ðÁý(ÀÇ·á±â±â)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
02.04 |
|
|
(ÁÖ)ÀÌÁö¼Ö·çÅØ |
GMP&Validation ä¿ë°ø°í
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
04.23 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] PV Associate ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
01.29 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] °æ·Â Clinical Research Associate ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
01.28 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] °æ·Â Project Managerä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
01.28 |
|
|
(ÁÖ)ÆÛ½¼ |
Á¦¾à¿µ¾÷ ´ã´çÀÚ Ã¤¿ë (Á¾ÇÕº´¿ø,ÀÇ¿ø) - ¼¿ï/°æ±â
¼¿ï ±Ýõ±¸, °æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
01.24 |
|
|
(ÁÖ)ÆÛ½¼ |
Á¦¾à¿µ¾÷(Á¾ÇÕº´¿ø,ÀÇ¿ø) - ¼¿ï/°æ±â
¼¿ï ±Ýõ±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
11.10 |
|
|
ºñº¸Á¸ |
ȸ°è/À繫 °æ·ÂÁ÷¿ø ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
8³â¡è |
ä¿ë½Ã |
12.07 |
|
|
(ÁÖ)¸ÞµåÆÄÅ© |
(ÁÖ)¸ÞµåÆÄÅ© (ºÎ»ê) ºê·£µù & ¸¶ÄÉÆà ( È«º¸ & ¾ð·Ð & ±¤°í
ºÎ»ê »ç»ó±¸ | Çз¹«°ü |
±¤°í/È«º¸/PR/»çº¸ |
3³â¡è |
ä¿ë½Ã |
05.24 |
|
|
Çѱ¹Organon |
Çѱ¹Organon Market Access ´ã´çÀÚ ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
01.15 |
|
|
ÁÖ½Äȸ»çÇ÷º½ÃÄɾîÄÚ¸®¾Æ |
Product specialist (ÀÎÇã°¡, º¸Çè, ¸¶ÄÉÆà ¾÷¹«)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
1³â¡è |
ä¿ë½Ã |
05.21 |
|
|
(ÁÖ)¸ÞµåÆÄÅ© |
ºê·£µå & µðÀÚÀÎ ±âȹȫº¸ ÃÑ°ý
¼¿ï ¿µµîÆ÷±¸ | Çз¹«°ü |
±¤°í/È«º¸/PR/»çº¸ |
5³â¡è |
ä¿ë½Ã |
05.24 |
|
|
(ÁÖ)¸ÞµåÆÄÅ© |
[»ç¼¼È®Àå/4,000¸¸ÀÌ»ó][¼¿ï/ºÎ»ê]±¹³»¿µ¾÷-Ä¡°úºÐ¾ß°æ·ÂÁ÷
¼¿ï ÀüÁö¿ª, ºÎ»ê ÀüÁö¿ª | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
02.23 |
|
|
(ÁÖ)¸ÞµåÆÄÅ© |
(ÁÖ)¸ÞµåÆÄÅ© [¼¿ï] Àλç / Ãѹ« °æ·Â ä¿ë
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
Àλç/ÀÎÀç°³¹ß/ä¿ë/±³À° |
5³â¡è |
ä¿ë½Ã |
02.23 |
|
|
(ÁÖ)¸ÞµåÆÄÅ© |
ÀÎüÁ¶Á÷»ç¾÷º»ºÎ Ã¥ÀÓ¿¬±¸¿ø ä¿ë
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
2³â¡è |
ä¿ë½Ã |
05.10 |
|